BPC-157 vs Orforglipron
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BPC-157
Body Protection Compound-157 is a synthetic peptide derived from a protein found in human gastric juice. It has shown remarkable healing properties in research studies.
Full details →Orforglipron
Orforglipron (LY3502970) is a non-peptide, oral GLP-1 receptor agonist developed by Eli Lilly. Unlike oral semaglutide (which is a peptide requiring special formulation), orforglipron is a small molecule — the first of a new class of oral GLP-1 drugs that can be taken without fasting restrictions. It is in Phase 3 trials for obesity and type 2 diabetes, with an FDA decision expected in 2026. Projected to reach $16 billion in annual sales by 2031.
Full details →Side-by-Side Comparison
| Aspect | BPC-157 | Orforglipron |
|---|---|---|
| Mechanism | BPC-157 works through multiple pathways including upregulation of growth factor expression, nitric oxide system modulation, and promotion of angiogenesis. It enhances tendon-to-bone healing and supports the formation of new blood vessels. | Orforglipron is a small-molecule agonist that binds and activates the GLP-1 receptor through the same signaling cascade as peptide GLP-1 agonists (cAMP elevation, insulin secretion, appetite suppression) but with a fundamentally different molecular structure. Being a non-peptide, it does not require protection from enzymatic degradation (no fatty acid conjugation needed), can be absorbed without special formulation, and has no fasting restrictions for administration. Once-daily oral dosing with a half-life of ~25-65 hours. |
| Typical Dosage | Typical research dosages range from 250-500mcg administered 1-2 times daily. Both subcutaneous and oral administration have been studied. | Phase 2 trial doses: 12 mg, 24 mg, 36 mg, and 45 mg daily. The 36 mg and 45 mg doses showed greatest efficacy. Phase 3 trials are evaluating doses of 12-60 mg daily. No fasting requirement — can be taken with or without food at any time of day. Final approved dosing not yet established. |
| Administration | Can be administered subcutaneously near the injury site or systemically. Stable in gastric juice, making oral administration viable. | Oral tablet, once daily. No fasting restrictions required (a major advantage over oral semaglutide). Phase 3 trials ongoing. Expected FDA decision in 2026. Not yet commercially available. |
| Side Effects | Generally well-tolerated in research. Some reports of mild nausea or dizziness at higher doses. | Phase 2 data: nausea (up to 35%), vomiting (up to 19%), diarrhea (up to 18%), constipation, decreased appetite. GI side effects were dose-dependent and generally transient, decreasing with continued use. Discontinuation rates due to GI events were 6-12%. |
| Best For |
Key Differences
Unique to BPC-157:
Unique to Orforglipron:
Detailed Analysis
Commonalities
BPC-157 and Orforglipron are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose BPC-157 for Muscle Growth, Recovery & Healing. Choose Orforglipron for Weight Loss, Diabetes Management.
Ready to Learn More?
Looking for trusted sources?